SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a steep selloff alongside other quantum-computing stocks, with traders citing high valuations, heavy losses and uncertainty over when the technology will generate meaningful commercial returns. Some see the decline as a buying opportunity, while others expect more downside and question whether upcoming results or company developments can reverse the trend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders positioning ahead of the Q3 report and watching BRIUMVI sales growth and guidance. Buyout and short-squeeze theories are also circulating, though some investors view the move as momentum ahead of earnings rather than evidence of a deal.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu shares are drawing attention after Lulas reelection triggered a sharp selloff across Brazilian stocks, with traders tying NUs decline to political and macroeconomic risk in its largest market rather than company-specific news. The community is split between viewing the move as an overreaction and buying opportunity, and expecting continued pressure from Brazil-related uncertainty.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have prompted concern about the slow launch of aldosterone-synthase inhibitors and the commercial outlook for Mineralys lorundrostat, contributing to MLYSs sharp decline. Some traders view the early sales as a coverage-access ramp rather than a verdict on demand, while others question whether Mineralys can compete and launch successfully on its own; its FDA decision remains a key milestone.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff after Intels weak forward guidance heightened concerns about PC demand and industry conditions. Traders point to the drop across chip peers, while some see the pullback as a buying opportunity ahead of Qualcomms earnings report.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is drawing attention for heavy call-option activity, while traders debate whether bullish positioning can outweigh elevated jet-fuel costs and the reduced profit outlook. Strong travel demand and pricing power are seen as offsets, but the sustainability of margins remains uncertain.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in London, Canada.

Aduro Clean Technologies Inc

Attention centers on Aduros progress toward commercializing its Hydrochemolytic Technology, including pilot results on mixed polyolefin feedstocks and engineering work for its planned Chemelot facility; some investors also see paraffinic crude as a potential nearer-term application. Bullish holders view these as validation, while skeptics argue the company has yet to demonstrate viable economics or commercial-scale performance.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters Q2 results have intensified debate over persistent broadband subscriber losses, competition and heavy debt, with concerns about weaker cash generation and paused buybacks weighing on sentiment. Bulls counter that the stocks low valuation, mobile growth and the Cox merger could support a recovery, while others remain skeptical about the deals added financing and dilution.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Discussion is focused on onsemis emerging AI/data-center exposure: traders point to growth in the Other end-market category, which includes computing and data centers, but question how durable that demand is because long-term supply agreements can be changed or canceled. The debate is tempered by the companys continued exposure to automotive and industrial markets facing a cyclical slowdown, alongside the stocks recent weakness.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons third-quarter results beat expectations, with strong refining profits and record operating performancesupported by elevated fuel margins amid supply disruptionsdriving the shares higher. Traders welcomed the results and shareholder-return plans, though some noted the stocks modest reaction and bearish put-heavy options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.read more...

Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know

Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday's clinical data webcast.read more...

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.81
Prev Close	$1.89
Open	$1.88
Dividend Yield	0.00%
50-Day Moving Average	$2.66
Beta	1.40
Avg. Volume	1.27M
PE Ratio	-1.29

52-Week High	$5.55
52-Week Low	$1.03
Market Capitalization	$216.45M
EPS (Annual)	-$1.28
Price to Book	10.04
Revenue Per Employee	$247,464.29

Feed

News

Sentiment

Earnings

Fundamentals

Info

PYXS Fundamentals